

Medsafe is seeking comments on:

The changes proposed to CMN Form B.	
<ul style="list-style-type: none"> Change of category name from 'Bulk Active methods of manufacture' to 'Active Ingredient methods of manufacture -Grade 1'. 	No issue. For consistency, it may also be advisable to change “Bulk active” to “active” throughout the document
<ul style="list-style-type: none"> Addition of 'Grade 2' to the existing category 'Active ingredient method of manufacture. 	No issue
<ul style="list-style-type: none"> Additional criteria under 'Active Ingredient methods of manufacture - Grade 1' to explain that changes to the manufacturing processes used for the isolation and purification of drug substance from plasma should be notified under this category. 	No issue
<ul style="list-style-type: none"> Introduction of a Self-assessable change notification (SACN) category 'Active ingredient method of manufacture - Grade 3' (fee \$360) 	No issue
<ul style="list-style-type: none"> Removal of the category 'Change in site of lyophilisation' (fee \$1440). Inclusion of a change in lyophilisation site under the category 'Finished product manufacturing site' (fee \$2880) 	No issue
<ul style="list-style-type: none"> Removal of the category 'Revalidation of the lyophilisation process' (fee \$1440). 	No issue
<ul style="list-style-type: none"> Introduction of the category 'Finished Product Testing site' (fee \$1440). 	The meaning of the second bullet point under FP testing site is unclear. This should be reworded for clearer definition or deleted.
<ul style="list-style-type: none"> Revision of the criteria for 'Finished Product manufacturing process - Grade 3' (fee \$720). 	No issue
<ul style="list-style-type: none"> Introduction of the SACN category 'Finished Product manufacturing process - Grade 4' (fee \$360). 	No issue
<ul style="list-style-type: none"> Editorial changes to criteria listed under the various 'Test methods and specifications' categories/grades. 	No issue
<ul style="list-style-type: none"> Introduction of categories for 'Excipient specifications/test methods'. 	No issue

<ul style="list-style-type: none"> Introduction of the category 'Shelf life/Storage conditions - Reference standard used for potency/assay' 	No issue
Additional Comments	
Change in ownership	Mylan supports the deletion of a change in ownership as requiring a CMN
Security labelling declaration	Mylan supports the removal of the requirement to provide a physical sample of the security label
Container/closure/packaging grade 3	We would propose the fee for this category is \$720 not \$780 to align with other similar categories of CMN
<p>Mylan also supports the comments made by the NZSMI with regard to changes proposed to Form A for these to also be applicable to Form B where there is overlap.</p> <p>Mylan would request that feedback is also accepted on Form B once the revised Form A is published for consultation by Medsafe to ensure consistency between product types.</p>	

Please include additional pages if necessary.